Number of Shares and Voting Rights of ADOCIA as of September 30th, 2024
08 Octobre 2024 - 6:00PM
Business Wire
Regulatory News:
Pursuant to the provisions of article L. 233-8 II of the French
« Code de Commerce » and article 223-16 of the French stock-market
authorities (Autorité des Marchés Financiers, or “AMF”) charter
ADOCIA SA (Paris:ADOC), a French société anonyme (corporation),
115, avenue Lacassagne, 69003 Lyon, (Euronext Paris: FR0011184241 –
ADOC) a clinical-stage biopharmaceutical Company focused on the
research and development of innovative therapeutic solutions for
the treatment of diabetes and obesity, releases its total number of
outstanding shares as well as its voting rights as of September
30th, 2024.
Month
Date
Total number of
outstanding shares
Total number of
theoretical voting
rights (1)
Total number of
exercisable voting
rights (2)
September
09/30/2024
15,246,638*
17,370,059
17,351,268
* 100 000 new shares have been issued over the month in
connection with the PACEO financing line, whose main
characteristics are described in our press release of March 21,
2024.
(1) The total number of theoretical voting rights (or “gross”
voting rights) is used as the basis for calculating the crossing of
shareholding thresholds. In accordance with Article 223-11 of the
AMF General Regulation, this number is calculated on the basis of
all shares to which voting rights are attached, including shares
whose voting rights have been suspended.
(2) The total number of exercisable voting rights (or” net”
voting rights) is calculated without taking into account the shares
with suspended voting rights, in this case, shares held by the
Company in the context of a liquidity agreement.
About Adocia
Adocia is a biotechnology company specializing in the discovery
and development of therapeutic solutions in the field of metabolic
diseases, primarily diabetes and obesity.
The company has a broad portfolio of drug candidates based on
four proprietary technology platforms: 1) The BioChaperone®
technology for the development of new generation insulins and
products combining different hormones; 2) AdOral®, an oral peptide
delivery technology; 3) AdoShell®, an immunoprotective biomaterial
for cell transplantation, with an initial application in pancreatic
cells transplantation; and 4) AdoGel®, a long-acting drug delivery
platform.
Adocia holds more than 25 patent families. Based in Lyon, the
company has about 80 employees. Adocia is listed on the regulated
market of Euronext™ Paris (Euronext: ADOC; ISIN: FR0011184241).
Disclaimer
This press release contains certain forward-looking statements
concerning Adocia and its business. Such forward-looking statements
are based on assumptions that Adocia considers as being reasonable.
However, there can be no guarantee that the estimates contained in
such forward-looking statements will be achieved, as such estimates
are subject to numerous risks including those set forth in the
“Risk Factors” section of the universal registration document that
was filed with the French Autorité des marchés financiers on April
29, 2024, as updated in the Company’s 2024 Half-year financial
statements, both available at www.adocia.com. Those risks include
uncertainties inherent in Adocia's short- or medium-term working
capital requirements, in research and development, future clinical
data, analyses and the evolution of economic conditions, the
financial markets and the markets in which Adocia operates, which
could impact the Company's short-term financing requirements and
its ability to raise additional funds. The forward-looking
statements contained in this press release are also subject to
risks not yet known to Adocia or not considered as material by
Adocia at this time. The occurrence of all or part of such risks
could cause the actual results, financial conditions, performances,
or achievements of Adocia be materially different from those
mentioned in the forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241008793854/en/
Adocia
Olivier Soula CEO contactinvestisseurs@adocia.com Tel :
+33 4 72 610 610 www.adocia.com
Ulysse Communication
Adocia Relations Presse et Investisseurs Bruno Arabian
Nicolas Entz adocia@ulysse-communication.com + 33 (0)6 87 88 47
26
Adocia (EU:ADOC)
Graphique Historique de l'Action
De Oct 2024 à Nov 2024
Adocia (EU:ADOC)
Graphique Historique de l'Action
De Nov 2023 à Nov 2024
